CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
Phase 2
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Neuroblastoma
Both
Neuroblastoma
Trial Information
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
Inclusion Criteria
Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor
histopathology or elevated urine VMA with typical tumor cells in the bone marrow.
Type of Study:
Interventional
Study Design:
Primary Purpose: Treatment
Authority:
United States: Federal Government
Study ID:
NCRR-M01RR00240-1748
NCT ID:
NCT00013806
Start Date:
Completion Date:
Related Keywords:
- Neuroblastoma
- Relapsed and refractory neuroblastoma
- Neuroblastoma
Name | Location |
|---|---|
| Children's Hospital of Philadelphia | Philadelphia, Pennsylvania 19104 |
